Williams T M, Moolten D M, Makni H, Kim H W, Kant J A, Kamoun M
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
J Immunol. 1992 Apr 15;148(8):2609-16.
CD28 is a glycoprotein expressed as a homodimer on the surface of a major subset of human T cells. Previous studies have shown that proliferation of peripheral blood T cells involving the CD28 pathway is associated with cyclosporine A (CsA) resistant IL-2 gene expression. This pathway was shown to specifically regulate the stability of mRNA for several lymphokines including IL-2. We have investigated the expression of the IL-2 gene in the Jurkat cell line, J32 clone, induced by CD28 stimulation. Cross-linked anti-CD28 mAb alone was sufficient to induce the release of small amounts of IL-2 (256 U/ml). The CD28-mediated IL-2 release was enhanced with simultaneous engagement of CD28 and CD2 or CD28 and CD3 molecules. Hybrid constructs in which the human IL-2 gene 5' flanking region drives luciferase expression (pIL-2-Luc) were used to help delineate whether the CD28 pathway activates the IL-2 gene transcriptionally. Costimulation of cells with CD28 mAb and either PHA or CD2 mAb induced a 20- to 90-fold increase in the expression of pIL-2-Luc as well as IL-2 release. Costimulation with CD28 mAb plus PMA gave only five- to sevenfold increase in enhancer activity. In contrast, no enhancer activity was detected after stimulation with CD28 or CD2 mAb alone. Both IL-2 release and pIL-2-Luc activity were inhibited by CsA in J32 cells. The degree of CsA inhibition was concentration dependent and was similar in cells stimulated with either CD28 mAb or CD3 mAb. Maximum inhibition was achieved with 1 microgram/ml of CsA. Studies with internal deletion mutations of the IL-2 gene 5' flanking sequence revealed that as with stimulation through the TCR pathway, the CD28 pathway requires 5' flanking sequences located within 500 bp of the transcription start site. These results are the first direct evidence that the triggering of CD28 molecule is sufficient to induce IL-2 release in J32 cells. Furthermore these studies strongly indicate that IL-2 gene expression induced by CD28 stimulation occurs, in part, transcriptionally and is CsA sensitive in these cells.
CD28是一种糖蛋白,以同源二聚体形式表达于人类T细胞主要亚群的表面。先前的研究表明,涉及CD28途径的外周血T细胞增殖与环孢素A(CsA)抗性白细胞介素-2(IL-2)基因表达相关。已证明该途径特异性调节包括IL-2在内的几种淋巴因子的mRNA稳定性。我们研究了CD28刺激诱导的Jurkat细胞系J32克隆中IL-2基因的表达。单独交联的抗CD28单克隆抗体足以诱导少量IL-2(256 U/ml)的释放。CD28和CD2或CD28和CD3分子同时结合可增强CD28介导的IL-2释放。用人IL-2基因5'侧翼区域驱动荧光素酶表达的杂交构建体(pIL-2-Luc)来帮助确定CD28途径是否在转录水平上激活IL-2基因。用CD28单克隆抗体与PHA或CD2单克隆抗体共同刺激细胞,可使pIL-2-Luc的表达以及IL-2释放增加20至90倍。用CD28单克隆抗体加佛波酯(PMA)共同刺激仅使增强子活性增加5至7倍。相比之下,单独用CD28或CD2单克隆抗体刺激后未检测到增强子活性。在J32细胞中,CsA可抑制IL-2释放和pIL-2-Luc活性。CsA的抑制程度呈浓度依赖性,在用CD28单克隆抗体或CD3单克隆抗体刺激的细胞中相似。1微克/毫升的CsA可实现最大抑制。对IL-2基因5'侧翼序列内部缺失突变的研究表明,与通过TCR途径刺激一样,CD28途径需要转录起始位点500 bp内的5'侧翼序列。这些结果是CD28分子的触发足以在J32细胞中诱导IL-2释放的首个直接证据。此外,这些研究强烈表明,CD28刺激诱导的IL-2基因表达部分发生在转录水平,并且在这些细胞中对CsA敏感。